In the AKT/NICD-induced spontaneous iCCA model, compared with monotherapy with anti-PD-1 antibody, AB680, or an IgG control, the combination therapy resulted in a significant reduction of tumor burden of primary iCCA revealed by the decreased liver weight versus body weight ratios (LW/BW) and number of tumor nodules (Fig. 5C-E). The gene discussed is AKT1; the disease is infantile convulsions and choreoathetosis.